Not content with the research side, NanoString places a lot of emphasis on its technology's usefulness in clinical settings for present-day patient care. Unfortunately, one of the biggest risk factors for this IPO is the company's consistent losses.
Genomics startup NanoString files for IPO in spite of consistent losses
Venture Beat - 20 May 2013 19:37
Not content with the research side, NanoString places a lot of emphasis on its technology's usefulness in clinical settings for present-day patient care. Unfortunately, one of the biggest risk factors for this IPO is the company's consistent losses.
Share this Article
Recommended